| Literature DB >> 25221976 |
Marília Baierle1, Patrícia H Vencato2, Luiza Oldenburg3, Suelen Bordignon4, Murilo Zibetti5, Clarissa M Trentini6, Marta M M F Duarte7, Juliana C Veit8, Sabrina Somacal9, Tatiana Emanuelli10, Tilman Grune11, Nicolle Breusing12, Solange C Garcia13.
Abstract
Polyunsaturated fatty acids (PUFAs), especially the n-3 series, are known for their protective effects. Considering that cardiovascular diseases are risk factors for dementia, which is common at aging, the aim of this study was to evaluate whether fatty acid status in the elderly was associated with cognitive function and cardiovascular risk. Forty-five elderly persons (age ≥ 60 years) were included and divided into two groups based on their Mini-Mental Status Examination score adjusted for educational level: the case group (n = 12) and the control group (n = 33). Serum fatty acid composition, homocysteine (Hcy), hs-CRP, lipid profile and different cognitive domains were evaluated. The case group, characterized by reduced cognitive performance, showed higher levels of 14:0, 16:0, 16:1n-7 fatty acids and lower levels of 22:0, 24:1n-9, 22:6n-3 (DHA) and total PUFAs compared to the control group (p < 0.05). The n-6/n-3 ratio was elevated in both study groups, whereas alterations in Hcy, hs-CRP and lipid profile were observed in the case group. Cognitive function was positively associated with the 24:1n-9, DHA and total n-3 PUFAs, while 14:0, 16:0 and 16:1n-7 fatty acids, the n-6/n-3 ratio and Hcy were inversely associated. In addition, n-3 PUFAs, particularly DHA, were inversely associated with cardiovascular risk, assessed by Hcy levels in the elderly.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25221976 PMCID: PMC4179179 DOI: 10.3390/nu6093624
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Baseline characteristics of the elderly: the case group (with cognitive impairment) and control group (without cognitive impairment).
| Parameter | Case ( | Control ( | Reference Values |
|---|---|---|---|
| Age (year) | 78.58 ± 2.57 | 73.33 ± 1.36 | |
| Male (%) | 25.0 | 36.4 | |
| Hypertension (%) | 66.7 | 66.7 | |
| Diabetes (%) | 8.3 | 24.2 | |
| GDS | 4.00 ± 0.99 | 4.42 ± 0.54 | |
| BMI (kg/m2) | 25.38 ± 1.03 | 26.43 ± 1.01 | |
| Total cholesterol (mg·dL−1) | 243.75 ± 12.69 b | 201.06 ± 8.22 | <200 |
| LDL cholesterol (mg·dL−1) | 154.33 ± 12.26 a | 121.88 ± 6.18 | <130 |
| HDL cholesterol (mg·dL−1) | 47.08 ± 2.23 | 54.39 ± 3.12 | >40 |
| Total cholesterol/HDL-C ratio | 5.33 ± 0.43 b | 3.92 ± 0.21 | <5 |
| Triglycerides (mg·dL−1) | 212.50 ± 21.97 b | 123.73 ± 9.61 | <150 |
Data are expressed as the mean and SEM or percentages. BMI, body mass index; GDS, geriatric depression scale; HDL, high-density lipoprotein; LDL, low-density lipoprotein. a p < 0.05; b p < 0.01 compared to the control group.
Serum fatty acid composition of subjects expressed as the percentage (%) of total fatty acids identified.
| Fatty Acid | Case ( | Control ( |
|---|---|---|
| 14:0 | 0.98 ± 0.10 b | 0.67 ± 0.05 |
| 16:0 | 24.11 ± 0.65 b | 21.36 ± 0.38 |
| 18:0 | 9.44 ± 0.61 | 10.21 ± 0.36 |
| 22:0 | 1.05 ± 0.11 b | 1.66 ± 0.12 |
| Σ Saturated | 35.58 ± 1.03 | 33.91 ± 0.56 |
| 16:1 | 2.14 ± 0.20 a | 1.60 ± 0.11 |
| 18:1 | 18.12 ± 0.69 | 16.99 ± 0.46 |
| 18:1 | 1.43 ± 0.08 | 1.32 ± 0.05 |
| 24:1 | 1.20 ± 0.09 b | 1.84 ± 0.14 |
| Σ Monounsaturated | 23.95 ± 1.17 | 22.58 ± 0.52 |
| 18:2 | 24.14 ± 1.17 | 25.70 ± 0.75 |
| 18:3 | 0.55 ± 0.11 | 0.32 ± 0.07 |
| 20:2 | 0.70 ± 0.23 | 0.77 ± 0.30 |
| 20:3 | 2.66 ± 0.23 | 2.88 ± 0.18 |
| 20:4 | 8.85 ± 0.48 | 9.79 ± 0.48 |
| Σ | 36.90 ± 0.95 | 39.46 ± 0.76 |
| 18:3 | 0.62 ± 0.08 | 0.84 ± 0.20 |
| 20:5 | 0.53 ± 0.09 | 0.51 ± 0.09 |
| 22:5 | 0.84 ± 0.14 | 0.52 ± 0.10 |
| 22:6 | 1.57 ± 0.14 a | 2.18 ± 0.18 |
| Σ | 3.57 ± 0.25 | 4.05 ± 0.36 |
| Σ Polyunsaturated | 40.47 ± 0.94 a | 43.51 ± 0.62 |
| 18:1 | 1.06 ± 0.56 | 0.85 ± 0.26 |
| Σ trans | 1.06 ± 0.56 | 0.85 ± 0.26 |
| 11.05 ± 1.09 | 13.99 ± 2.69 |
Data are expressed as the mean ± SEM. a p < 0.05; b p < 0.01 compared to the control group (elderly subjects without cognitive impairment). The fatty acids, 4:0, 6:0, 8:0, 11:0, 12:0, 13:0, 14:1n-5, 15:0, 15:1n-5, 17:0, 17:1n-7, 18:2n-6t, 20:0, 20:1n-9, 21:0, 20:3n-3, 22:1n-9, 22:2n-6, 22:4n-6, 22:5-n6, 23:0, 24:0, were not detected in the samples.
Cognitive performance of the studied groups in thedifferent applied instruments.
| Instrument | Case ( | Control ( |
|---|---|---|
| MMSE | 16.50 ± 1.24 b | 26.76 ± 0.38 |
| Verbal Fluency | 8.91 ± 0.99 b | 15.94 ± 1.04 |
| Boston’s Naming Test | 8.50 ± 0.74 b | 12.97 ± 0.38 |
| Word List Memory | 9.08 ± 1.41 b | 15.30 ± 0.84 |
| Delay Recall of Word List | 1.92 ± 0.67 a | 4.64 ± 0.47 |
| Recognition Word List | 6.10 ± 1.05 | 8.24 ± 0.40 |
| Constructional Praxis | 5.20 ± 0.73 b | 8.91 ± 0.30 |
| Delay Visual Memory | 1.75 ± 0.73 b | 6.41 ± 0.63 |
| Trails Test A time (s) | 167.00 ± 42.89 a | 85.50 ± 7.21 |
| Trails Test B time (s) | 268.33 ± 31.67 | 187.29 ± 16.04 |
| WAIS-III Digits | 7.17 ± 0.74 b | 10.45 ± 0.47 |
The values were adjusted for age and expressed as the mean ± SEM. MMSE, Mini-Mental Status Examination; WAIS-III, Wechsler Adult Intelligence Scale III Edition. a p < 0.05; b p < 0.01 compared to the control group (elderly subjects without cognitive impairment).
Correlation coefficients (r) between cognitive performance (different applied instruments) and fatty acids (n = 45).
| Instrument | 14:0 | 16:0 | 16:1 | 24:1 | 20:4 | 22:6 | Σ | |
|---|---|---|---|---|---|---|---|---|
| MMSE | −0.597 b | −0.396 b | −0.405 b | 0.472 b | 0.137 | 0.546 b | 0.463 b | −0.438 b |
| Verbal Fluency | −0.544 b | −0.230 | −0.423 b | 0.367 a | 0.065 | 0.257 | 0.225 | −0.242 |
| Boston’s Naming Test | −0.499 b | −0.229 | −0.429 b | 0.543 b | 0.256 | 0.388 b | 0.224 | −0.251 |
| Word List Memory | −0.534 b | −0.123 | −0.387 b | 0.365 a | 0.262 | 0.417 b | 0.423 b | −0.482 b |
| Delay Recall of Word List | −0.427 b | −0.187 | −0.364 a | 0.231 | 0.251 | 0.447 b | 0.428 b | −0.476 b |
| Recognition Word List | −0.437 b | −0.158 | −0.430 b | 0.085 | 0.331 | 0.513 b | 0.437 b | −0.401 b |
| Constructional Praxis | −0.531 b | −0.438 b | −0.417 b | 0.326 a | 0.044 | 0.148 | 0.113 | −0.113 |
| Delay Visual Memory | −0.569 b | −0.421 b | −0.369 a | 0.330 a | 0.167 | 0.322 a | 0.291 | −0.355 a |
| Trials Test A time | 0.545 b | 0.131 | 0.453 b | −0.334 a | −0.115 | −0.436 b | −0.476 b | 0.460 b |
| Trials Test B time | 0.424 a | 0.189 | 0.221 | −0.361 a | 0.153 | −0.335 a | −0.387 a | 0.441 a |
| WAIS-III Digits | −0.267 | −0.166 | −0.082 | 0.382 b | −0.287 | 0.192 | 0.217 | −0.287 |
MMSE, Mini-Mental Status Examination; WAIS-III, Wechsler Adult Intelligence Scale III Edition; PUFAs, polyunsaturated fatty acids. a p < 0.05; b p < 0.01.
Figure 1(A) Homocysteine (Hcy) and (B) hs-CRP levels in elderly subjects with (case) and without (control) cognitive impairment. Data are expressed as the mean ± SEM. * p < 0.05. Correlations between homocysteine vs.: (C) 22:6n-3; (D) 20:5n-3; (E) Σ n-3 polyunsaturated; and (F) the n-6/n-3 ratio. In each analysis, n = 45.
Correlations between homocysteine (Hcy) levels vs. cognitive performance, using different instruments. In each analysis, n = 45.
| Instrument | Hcy (μmol·L−1) |
|---|---|
| MMSE | −0.332 a |
| Verbal Fluency | −0.153 |
| Boston’s Naming Test | −0.180 |
| Word List Memory | −0.370 a |
| Delay Recall of Word List | −0.396 b |
| Recognition Word List | −0.262 |
| Constructional Praxis | −0.251 |
| Delay Visual Memory | −0.190 |
| Trials Test A time | 0.317 |
| Trials Test B time | 0.383 a |
| WAIS-III Digits | −0.306 a |
MMSE, Mini-Mental Status Examination; WAIS-III, Wechsler Adult Intelligence Scale III Edition; a p < 0.05; b p < 0.01.